Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies.
Bi-specific anti-CD33 x anti-CD64 antibodies (BsAb) mediated more potent and longer-lasting inhibition of proliferation of human leukemia cell lines and primary acute myeloid leukemia (AML) samples compared to mono-specific anti-CD33 mAb. There were no differences between these two antibodies in cellular internalization over time. The inhibitory effect of BsAb was mimicked by a mouse IgG2a subclass mono-specific anti-CD33 mAb. These findings indicate that enhanced inhibition of proliferation was caused by simultaneous ligation of both CD33 and CD64 molecules. We conclude that inhibition of leukemia cell growth initiated by BsAb during prolonged exposure may have therapeutic value for the treatment of AML.
Balaian
Larisa
L
Department of Medicine and Cancer Center, University of California, San Diego School of Medicine, La Jolla, CA, USA.
Ball
Edward D
ED
D000208:Acute Disease; D018033:Antibodies, Bispecific / Q000494:pharmacology*; D015703:Antigens, CD / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology / Q000473:pathology*; D017452:Receptors, IgG / Q000276:immunology*; D063268:Sialic Acid Binding Ig-like Lectin 3; D020298:U937 Cells
D018033:Antibodies, Bispecific; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; C571165:Cd33 protein, mouse; D017452:Receptors, IgG; D063268:Sialic Acid Binding Ig-like Lectin 3